Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Recursion Pharmaceuticals , Inc. (NASDAQ:RXRX), currently trading at $5.11 after declining over 10% in the past week, announced the results of its 2025 annual meeting of stockholders held on Wednesday. According to InvestingPro analysis, the company maintains a strong liquidity position with cash exceeding debt, though it faces challenges with rapid cash burn.
Stockholders approved all proposals presented at the meeting, according to an SEC filing. The company’s Class I directors were elected to serve until the 2028 annual meeting, with Zachary Bogue receiving the strongest support at 242,298,743 votes in favor and 3,971,237 votes withheld. Zavain Dar secured 203,315,209 favorable votes with 42,954,771 withheld, while Robert Hershberg received 233,487,438 votes in favor and 12,782,542 withheld.
The advisory resolution on executive compensation passed with 239,911,332 votes in favor, 3,242,536 against, and 3,116,112 abstentions.
Stockholders also ratified the appointment of PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. This proposal received 334,613,329 votes in favor, 1,968,162 against, and 3,058,267 abstentions.
Recursion Pharmaceuticals is a biotechnology company based in Salt Lake City, Utah, focused on biological products. The voting results were disclosed in a Form 8-K filed with the Securities and Exchange Commission.
In other recent news, Recursion Pharmaceuticals has been active with several noteworthy developments. The company announced the release of Boltz-2, an AI model developed in collaboration with MIT, aimed at enhancing drug discovery processes. This model is reported to operate significantly faster than current standards, offering improved accuracy in predicting molecular structures and binding affinities. In financial updates, Recursion filed a prospectus supplement to register the resale of approximately 4.26 million shares issued to Tempus Labs, Inc., as part of an agreement between the two companies. Morgan Stanley (NYSE:MS) adjusted its price target for Recursion to $5.00, citing strategic pipeline prioritizations and cost reductions. Similarly, BofA Securities revised its target to $8.00 following the company’s decision to deprioritize several pipeline programs. Recursion’s recent partnership advancements include a $7 million milestone payment from Sanofi (NASDAQ:SNY), part of a potential $300 million deal. The company reported having $509 million in cash reserves, expected to support operations until mid-2027.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.